Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.64 |
| ▸ | LMNA | P02545 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902631 | 0.86 | TP53 (0.72) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL5324086 | 0.84 | HSD17B10 (0.61) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL901637 | 0.83 | TP53 (0.56) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL4794949 | 0.83 | TP53 (0.67) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL13413800 | 0.82 | TP53 (0.51) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL902519 | 0.81 | TP53 (0.55) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL21159868 | 0.81 | ALDH1A1 (0.66) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL4794397 | 0.80 | TP53 (0.72) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL902516 | 0.80 | TP53 (0.54) | TP53LMNAMAPTHPGDKDM4E | |
| SCHEMBL22680753 | 0.79 | LMNA (0.58) | TP53LMNAMAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | claimed |
| EP-2621928-A1 | 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-07 | — | — | EP | claimed |
| WO-2012041817-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-05 | — | — | WO | claimed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| EP-2621928-A1 | 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041817-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR5, CCR1 | TP53 2371/4885LMNA 4062/4885MAPT 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.